

China Urological Cancer Drugs Market Research Report 2017

<https://marketpublishers.com/r/CC899694B46EN.html>

Date: February 2017

Pages: 122

Price: US\$ 3,200.00 (Single User License)

ID: CC899694B46EN

Abstracts

Notes:

Sales, means the sales volume of Urological Cancer Drugs

Revenue, means the sales value of Urological Cancer Drugs

This report studies Urological Cancer Drugs in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.

Tolmar Inc

Market Segment by Regions (provinces), covering

South China

East China

Southwest China

Northeast China

North China

Central China

Northwest China

Split by product Type, with production, revenue, price, market share and growth rate of each type, can be divided into

Xofigo (Radium Ra 223 Dichloride)

Jevtana (Cabazitaxel)

Inlyta (Axitinib)

Votrient (Pazopanib Hydrochloride)

Sutent (Sunitinib Malate)

Zytiga (Abiraterone Acetate)

Xtandi (Enzalutamide)

Opdivo (Nivolumab)

Provenge (Sipuleucel-T)

Split by Application, this report focuses on consumption, market share and growth rate of Urological Cancer Drugs in each application, can be divided into

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

Contents

China Urological Cancer Drugs Market Research Report 2017

1 UROLOGICAL CANCER DRUGS MARKET OVERVIEW

- 1.1 Product Overview and Scope of Urological Cancer Drugs
- 1.2 Urological Cancer Drugs Segment by Type
 - 1.2.1 China Production Market Share of Urological Cancer Drugs Type in 2015
 - 1.2.2 Xofigo (Radium Ra 223 Dichloride)
 - 1.2.3 Jevtana (Cabazitaxel)
 - 1.2.4 Inlyta (Axitinib)
 - 1.2.5 Votrient (Pazopanib Hydrochloride)
 - 1.2.6 Sutent (Sunitinib Malate)
 - 1.2.7 Zytiga (Abiraterone Acetate)
 - 1.2.8 Xtandi (Enzalutamide)
 - 1.2.9 Opdivo (Nivolumab)
 - 1.2.10 Provenge (Sipuleucel-T)
- 1.3 Applications of Urological Cancer Drugs
 - 1.3.1 Urological Cancer Drugs Consumption Market Share by Application in 2015
 - 1.3.2 Prostate Cancer
 - 1.3.3 Bladder Cancer
 - 1.3.4 Kidney Cancer
 - 1.3.5 Testicular Cancer
- 1.4 China Market Size (Value) of Urological Cancer Drugs (2012-2022)
- 1.5 China Urological Cancer Drugs Status and Outlook
- 1.6 Government Policies

2 CHINA UROLOGICAL CANCER DRUGS MARKET COMPETITION BY MANUFACTURERS

- 2.1 China Urological Cancer Drugs Capacity, Production and Share by Manufacturers (2015 and 2016)
- 2.2 China Urological Cancer Drugs Revenue and Share by Manufacturers (2015 and 2016)
- 2.3 China Urological Cancer Drugs Average Price by Manufacturers (2015 and 2016)
- 2.4 Manufacturers Urological Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Type
- 2.5 Urological Cancer Drugs Market Competitive Situation and Trends

2.5.1 Urological Cancer Drugs Market Concentration Rate

2.5.2 Urological Cancer Drugs Market Share of Top 3 and Top 5 Manufacturers

3 CHINA UROLOGICAL CANCER DRUGS MANUFACTURERS PROFILES/ANALYSIS

3.1 Novartis

3.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.1.2 Urological Cancer Drugs Product Type, Application and Specification

3.1.2.1 Xofigo (Radium Ra 223 Dichloride)

3.1.2.2 Jevtana (Cabazitaxel)

3.1.3 Novartis Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.1.4 Main Business/Business Overview

3.2 Pfizer

3.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.2.2 Urological Cancer Drugs Product Type, Application and Specification

3.2.2.1 Xofigo (Radium Ra 223 Dichloride)

3.2.2.2 Jevtana (Cabazitaxel)

3.2.3 Pfizer 122 Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.2.4 Main Business/Business Overview

3.3 Johnson & Johnson

3.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.3.2 Urological Cancer Drugs Product Type, Application and Specification

3.3.2.1 Xofigo (Radium Ra 223 Dichloride)

3.3.2.2 Jevtana (Cabazitaxel)

3.3.3 Johnson & Johnson 127 Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.3.4 Main Business/Business Overview

3.4 AstraZeneca

3.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.4.2 Urological Cancer Drugs Product Type, Application and Specification

3.4.2.1 Xofigo (Radium Ra 223 Dichloride)

3.4.2.2 Jevtana (Cabazitaxel)

3.4.3 AstraZeneca Jan Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.4.4 Main Business/Business Overview

3.5 Astellas

3.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.5.2 Urological Cancer Drugs Product Type, Application and Specification

3.5.2.1 Xofigo (Radium Ra 223 Dichloride)

3.5.2.2 Jevtana (Cabazitaxel)

3.5.3 Astellas Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.5.4 Main Business/Business Overview

3.6 Bristol-Myers Squibb

3.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.6.2 Urological Cancer Drugs Product Type, Application and Specification

3.6.2.1 Xofigo (Radium Ra 223 Dichloride)

3.6.2.2 Jevtana (Cabazitaxel)

3.6.3 Bristol-Myers Squibb Million USD Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.6.4 Main Business/Business Overview

3.7 Abbott Laboratories

3.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.7.2 Urological Cancer Drugs Product Type, Application and Specification

3.7.2.1 Xofigo (Radium Ra 223 Dichloride)

3.7.2.2 Jevtana (Cabazitaxel)

3.7.3 Abbott Laboratories Pharma & Healthcare Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.7.4 Main Business/Business Overview

3.8 Celgene Corporation

3.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.8.2 Urological Cancer Drugs Product Type, Application and Specification

3.8.2.1 Xofigo (Radium Ra 223 Dichloride)

3.8.2.2 Jevtana (Cabazitaxel)

3.8.3 Celgene Corporation Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.8.4 Main Business/Business Overview

3.9 Dendreon Corporation

3.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.9.2 Urological Cancer Drugs Product Type, Application and Specification

3.9.2.1 Xofigo (Radium Ra 223 Dichloride)

3.9.2.2 Jevtana (Cabazitaxel)

3.9.3 Dendreon Corporation Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.9.4 Main Business/Business Overview

3.10 Ferring Pharmaceuticals

3.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

3.10.2 Urological Cancer Drugs Product Type, Application and Specification

3.10.2.1 Xofigo (Radium Ra 223 Dichloride)

3.10.2.2 Jevtana (Cabazitaxel)

3.10.3 Ferring Pharmaceuticals Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)

3.10.4 Main Business/Business Overview

3.11 GlaxoSmithKline

3.12 Indevus Pharmaceuticals Inc

3.13 Ipsen

3.14 Roche Healthcare

3.15 Sanofi S.A.

3.16 Tolmar Inc

4 CHINA UROLOGICAL CANCER DRUGS CAPACITY, PRODUCTION, REVENUE, CONSUMPTION, EXPORT AND IMPORT (2012-2017)

4.1 China Urological Cancer Drugs Capacity, Production and Growth (2012-2017)

4.2 China Urological Cancer Drugs Revenue and Growth (2012-2017)

4.3 China Urological Cancer Drugs Production, Consumption, Export and Import (2012-2017)

5 CHINA UROLOGICAL CANCER DRUGS PRODUCTION, REVENUE (VALUE), PRICE TREND BY TYPE

5.1 China Urological Cancer Drugs Production and Market Share by Type (2012-2017)

5.2 China Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)

5.3 China Urological Cancer Drugs Price by Type (2012-2017)

5.4 China Urological Cancer Drugs Production Growth by Type (2012-2017)

6 CHINA UROLOGICAL CANCER DRUGS MARKET ANALYSIS BY APPLICATION

6.1 China Urological Cancer Drugs Consumption and Market Share by Application (2012-2017)

6.2 China Urological Cancer Drugs Consumption Growth Rate by Application (2012-2017)

6.3 Market Drivers and Opportunities

6.3.1 Potential Application

6.3.2 Emerging Markets/Countries

7 CHINAUROLOGICAL CANCER DRUGS MARKET ANALYSIS BY REGIONS (PROVINCES)

7.1 China Urological Cancer Drugs Production, Production Value and Price by Regions (Provinces)(2012-2017)

7.1.1 China Urological Cancer Drugs Production and Market Share by Regions (Provinces)(2012-2017)

7.1.2 China Urological Cancer Drugs Production Value and Market Share by Regions (Provinces)(2012-2017)

7.1.3 China Urological Cancer Drugs Sales Price by Regions (Provinces)(2012-2017)

7.2 China Urological Cancer Drugs Consumption by Regions (Provinces)(2012-2017)

7.3 China Urological Cancer Drugs Production, Consumption, Export and Import (2012-2017)

8 UROLOGICAL CANCER DRUGS MANUFACTURING COST ANALYSIS

8.1 Urological Cancer Drugs Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Price Trend of Key Raw Materials

8.1.3 Key Suppliers of Raw Materials

8.1.4 Market Concentration Rate of Raw Materials

8.2 Proportion of Manufacturing Cost Structure

8.2.1 Raw Materials

8.2.2 Labor Cost

8.2.3 Manufacturing Expenses

8.3 Manufacturing Process Analysis of Urological Cancer Drugs

9 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

- 9.1 Urological Cancer Drugs Industrial Chain Analysis
- 9.2 Upstream Raw Materials Sourcing
- 9.3 Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015
- 9.4 Downstream Buyers

10 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

11 MARKET EFFECT FACTORS ANALYSIS

- 11.1 Technology Progress/Risk
 - 11.1.1 Substitutes Threat
 - 11.1.2 Technology Progress in Related Industry
- 11.2 Consumer Needs/Customer Preference Change
- 11.3 Economic/Political Environmental Change

12 CHINA UROLOGICAL CANCER DRUGS MARKET FORECAST (2017-2022)

- 12.1 China Urological Cancer Drugs Capacity, Production, Revenue Forecast (2017-2022)
- 12.2 China Urological Cancer Drugs Production, Import, Export and Consumption Forecast (2017-2022)
- 12.3 China Urological Cancer Drugs Production Forecast by Type (2017-2022)
- 12.4 China Urological Cancer Drugs Consumption Forecast by Application (2017-2022)
- 12.5 China Urological Cancer Drugs Production, Consumption, Import and Export Forecast by Regions (Provinces)(2017-2022)
 - 12.5.1 China Urological Cancer Drugs Production Forecast by Regions (Provinces)(2017-2022)

12.5.2 China Urological Cancer Drugs Consumption Forecast by Regions
(Provinces)(2017-2022)

12.5.3 China Urological Cancer Drugs Production, Consumption, Import and Export
Forecast by Regions (Provinces)(2017-2022)

12.6 Urological Cancer Drugs Price Forecast (2017-2022)

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

Methodology

Analyst Introduction

Data Source

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Urological Cancer Drugs
Figure China Production Market Share of Urological Cancer Drugs by Type in 2015
Figure Product Picture of Xofigo (Radium Ra 223 Dichloride)
Table Major Manufacturers of Xofigo (Radium Ra 223 Dichloride)
Figure Product Picture of Jevtana (Cabazitaxel)
Table Major Manufacturers of Jevtana (Cabazitaxel)
Figure Product Picture of Inlyta (Axitinib)
Table Major Manufacturers of Inlyta (Axitinib)
Figure Product Picture of Votrient (Pazopanib Hydrochloride)
Table Major Manufacturers of Votrient (Pazopanib Hydrochloride)
Figure Product Picture of Sutent (Sunitinib Malate)
Table Major Manufacturers of Sutent (Sunitinib Malate)
Figure Product Picture of Zytiga (Abiraterone Acetate)
Table Major Manufacturers of Zytiga (Abiraterone Acetate)
Figure Product Picture of Xtandi (Enzalutamide)
Table Major Manufacturers of Xtandi (Enzalutamide)
Figure Product Picture of Opdivo (Nivolumab)
Table Major Manufacturers of Opdivo (Nivolumab)
Figure Product Picture of Provenge (Sipuleucel-T)
Table Major Manufacturers of Provenge (Sipuleucel-T)
Table Urological Cancer Drugs Consumption Market Share by Application in 2015
Figure Prostate Cancer Examples
Figure Bladder Cancer Examples
Figure Kidney Cancer Examples
Figure Testicular Cancer Examples
Figure China Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Table China Urological Cancer Drugs Capacity of Key Manufacturers (2015 and 2016)
Table China Urological Cancer Drugs Capacity Market Share of Key Manufacturers (2015 and 2016)
Figure China Urological Cancer Drugs Capacity of Key Manufacturers in 2015
Figure China Urological Cancer Drugs Capacity of Key Manufacturers in 2016
Table China Urological Cancer Drugs Production of Key Manufacturers (2015 and 2016)
Table China Urological Cancer Drugs Production Share by Manufacturers (2015 and

2016)

Figure 2015 Urological Cancer Drugs Production Share by Manufacturers

Figure 2016 Urological Cancer Drugs Production Share by Manufacturers

Table China Urological Cancer Drugs Revenue (Million USD) by Manufacturers (2015 and 2016)

Table China Urological Cancer Drugs Revenue Share by Manufacturers (2015 and 2016)

Table 2015 China Urological Cancer Drugs Revenue Share by Manufacturers

Table 2016 China Urological Cancer Drugs Revenue Share by Manufacturers

Table China Market Urological Cancer Drugs Average Price of Key Manufacturers (2015 and 2016)

Figure China Market Urological Cancer Drugs Average Price of Key Manufacturers in 2015

Table Manufacturers Urological Cancer Drugs Manufacturing Base Distribution and Sales Area

Table Manufacturers Urological Cancer Drugs Product Type

Figure Urological Cancer Drugs Market Share of Top 3 Manufacturers

Figure Urological Cancer Drugs Market Share of Top 5 Manufacturers

Table Novartis Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Novartis Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Novartis Urological Cancer Drugs Market Share (2012-2017)

Table Pfizer Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Pfizer Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Pfizer Urological Cancer Drugs Market Share (2012-2017)

Table Johnson & Johnson Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Johnson & Johnson Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Johnson & Johnson Urological Cancer Drugs Market Share (2012-2017)

Table AstraZeneca Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table AstraZeneca Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure AstraZeneca Urological Cancer Drugs Market Share (2012-2017)

Table Astellas Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Astellas Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Astellas Urological Cancer Drugs Market Share (2012-2017)

Table Bristol-Myers Squibb Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Bristol-Myers Squibb Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Bristol-Myers Squibb Urological Cancer Drugs Market Share (2012-2017)

Table Abbott Laboratories Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Abbott Laboratories Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Abbott Laboratories Urological Cancer Drugs Market Share (2012-2017)

Table Celgene Corporation Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Celgene Corporation Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Celgene Corporation Urological Cancer Drugs Market Share (2012-2017)

Table Dendreon Corporation Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Dendreon Corporation Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Dendreon Corporation Urological Cancer Drugs Market Share (2012-2017)

Table Ferring Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Ferring Pharmaceuticals Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

Figure Ferring Pharmaceuticals Urological Cancer Drugs Market Share (2012-2017)

Table GlaxoSmithKline Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Indevus Pharmaceuticals Inc Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Ipsen Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Roche Healthcare Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Sanofi S.A. Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Tolmar Inc Basic Information, Manufacturing Base, Sales Area and Its Competitors

Figure China Urological Cancer Drugs Capacity, Production and Growth (2012-2017)

Figure China Urological Cancer Drugs Revenue (Million USD) and Growth (2012-2017)

Table China Urological Cancer Drugs Production, Consumption, Export and Import (2012-2017)

Table China Urological Cancer Drugs Production by Type (2012-2017)

Table China Urological Cancer Drugs Production Share by Type (2012-2017)

Figure Production Market Share of Urological Cancer Drugs by Type (2012-2017)

Figure 2015 Production Market Share of Urological Cancer Drugs by Type

Table China Urological Cancer Drugs Revenue by Type (2012-2017)

Table China Urological Cancer Drugs Revenue Share by Type (2012-2017)

Figure Production Revenue Share of Urological Cancer Drugs by Type (2012-2017)

Figure 2015 Revenue Market Share of Urological Cancer Drugs by Type

Table China Urological Cancer Drugs Price by Type (2012-2017)

Figure China Urological Cancer Drugs Production Growth by Type (2012-2017)

Table China Urological Cancer Drugs Consumption by Application (2012-2017)

Table China Urological Cancer Drugs Consumption Market Share by Application (2012-2017)

Figure China Urological Cancer Drugs Consumption Market Share by Application in 2015

Table China Urological Cancer Drugs Consumption Growth Rate by Application (2012-2017)

Figure China Urological Cancer Drugs Consumption Growth Rate by Application (2012-2017)

Table China Urological Cancer Drugs Production by Regions (Provinces)(2012-2017)

Table China Urological Cancer Drugs Production Market Share by Regions (Provinces)(2012-2017)

Table China Urological Cancer Drugs Production Value by Regions (Provinces)(2012-2017)

Table China Urological Cancer Drugs Production Value Market Share by Regions (Provinces)(2012-2017)

Table China Urological Cancer Drugs Sales Price by Regions (Provinces)(2012-2017)

Table China Urological Cancer Drugs Consumption by Regions (Provinces)(2012-2017)

Table China Urological Cancer Drugs Consumption Market Share by Regions (Provinces)(2012-2017)

Table China Urological Cancer Drugs Production, Consumption, Export and Import (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Urological Cancer Drugs

Figure Manufacturing Process Analysis of Urological Cancer Drugs

Figure Urological Cancer Drugs Industrial Chain Analysis

Table Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015

Table Major Buyers of Urological Cancer Drugs

Table Distributors/Traders List

Figure China Urological Cancer Drugs Capacity, Production and Growth Rate Forecast (2017-2022)

Figure China Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)

Table China Urological Cancer Drugs Production, Import, Export and Consumption Forecast (2017-2022)

Table China Urological Cancer Drugs Production Forecast by Type (2017-2022)

Table China Urological Cancer Drugs Consumption Forecast by Application (2017-2022)

Table China Urological Cancer Drugs Production Forecast by Regions (Provinces)(2017-2022)

Table China Urological Cancer Drugs Consumption Forecast by Regions (Provinces)(2017-2022)

Table China Urological Cancer Drugs Production, Consumption, Import and Export Forecast by Regions (Provinces)(2017-2022)

I would like to order

Product name: China Urological Cancer Drugs Market Research Report 2017

Product link: <https://marketpublishers.com/r/CC899694B46EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC899694B46EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970